List of Excipients in Branded Drug SUTAB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	SUTAB	sodium sulfate, magnesium sulfate, and potassium chloride	24338-201	ETHYLENE GLYCOL
Azurity Pharmaceuticals Inc	SUTAB	sodium sulfate, magnesium sulfate, and potassium chloride	24338-201	POLYETHYLENE GLYCOL 8000
Azurity Pharmaceuticals Inc	SUTAB	sodium sulfate, magnesium sulfate, and potassium chloride	24338-201	POLYVINYL ALCOHOL GRAFT POLYETHYLENE GLYCOL COPOLYMER
Azurity Pharmaceuticals Inc	SUTAB	sodium sulfate, magnesium sulfate, and potassium chloride	24338-201	SODIUM CAPRYLATE
Braintree Laboratories Inc	SUTAB	sodium sulfate, magnesium sulfate, and potassium chloride	52268-201	ETHYLENE GLYCOL

SUTAB Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

SUTAB is a prescription tablet bowel-preparation product containing sodium sulfate, magnesium sulfate, and potassium chloride. Its commercial differentiation comes from replacing a large-volume liquid preparation with 24 tablets and a required volume of water. The main excipient opportunities are tablet size reduction, mechanical robustness, moisture control, swallowability, manufacturing yield, and generic-equivalence design.

SUTAB’s formulation is commercially defensible because the active salts are used in high quantities and must remain stable, compressible, rapidly dispersible, and acceptable for oral administration. The product is not a biologic, so biosimilar pathways do not apply. Competition is more likely to come from generic tablets, alternative solid oral bowel preparations, branded liquid products, and lower-cost combination regimens.

What is SUTAB and how does its formulation work?

SUTAB is an oral osmotic laxative tablet approved by the U.S. Food and Drug Administration in December 2018 for colon cleansing before colonoscopy in adults. Each tablet contains:

Component	Amount per tablet	Function
Sodium sulfate	1.479 g	Osmotic cleansing agent
Magnesium sulfate	0.225 g	Osmotic cleansing agent
Potassium chloride	0.188 g	Electrolyte component
Total active salts	1.892 g	Primary pharmacologic load

The labeled regimen requires 12 tablets with water in the evening before colonoscopy and another 12 tablets on the morning of the procedure. Patients must drink additional water with each dose. The total daily active-salt load is approximately 45.4 g across 24 tablets, excluding water intake and excipients. [1]

SUTAB is marketed by Sebela Pharmaceuticals. The product was developed by Braintree Laboratories, which was acquired by Sebela in 2016. FDA approval established a tablet-based alternative to polyethylene glycol and sulfate-based liquid bowel preparations. [2]

What excipients are used in SUTAB tablets?

The FDA-approved label identifies crospovidone, magnesium stearate, microcrystalline cellulose, and silicon dioxide as inactive ingredients. [1]

Excipient	Formulation role	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet strength and manufacturing throughput
Crospovidone	Superdisintegrant	Promotes rapid breakup of a high-salt tablet
Magnesium stearate	Lubricant	Reduces tablet ejection force and tooling adhesion
Silicon dioxide	Glidant and moisture-control aid	Improves powder flow and reduces processing variability

The formulation has a narrow design space. Increasing excipient content can improve compression and disintegration but also increases tablet size. Because patients must swallow 24 tablets, any increase in tablet dimensions directly affects adherence and product acceptability.

Why does tablet size matter commercially?

The active ingredients account for most of the tablet mass. Excipient optimization therefore cannot reduce the principal burden through ordinary filler substitution. Commercial improvements must come from:

• Higher tablet tensile strength at lower compression force
• Better powder flow and die filling
• Reduced tablet friability
• Faster disintegration after ingestion
• Lower lubricant concentration
• More efficient granulation or direct-compression processing
• Reduced moisture uptake during storage

A smaller tablet could improve patient acceptance, but the achievable reduction is limited by the mass of the sulfate and chloride salts. A more realistic opportunity is improving tablet geometry, surface finish, swallowability, and packaging rather than pursuing a major reduction in total mass.

What excipient strategies can improve SUTAB performance?

Can direct compression improve SUTAB manufacturing?

Direct compression is attractive because it eliminates wet granulation, reduces processing steps, and can lower manufacturing cost. The principal risks are poor flow, segregation between salts and excipients, variable tablet weight, and insufficient mechanical strength.

A commercial direct-compression platform would need to control:

1. Particle-size distribution for each active salt.
2. Bulk density and flow properties.
3. Blend segregation during transfer and compression.
4. Lubrication time and magnesium stearate distribution.
5. Tablet tensile strength and friability.
6. Disintegration after exposure to water.

A co-processed excipient system could be valuable if it improves flow and compressibility without increasing tablet volume. However, a new excipient combination may create additional formulation-development and equivalence work for an ANDA applicant.

Can alternative disintegrants create a competitive advantage?

Crospovidone is already used to promote tablet breakup. Alternative or supplemental disintegrants could include croscarmellose sodium or sodium starch glycolate. Their commercial value would depend on whether they improve disintegration without increasing swelling, tablet size, or dissolution variability.

The most useful strategy is likely a low-level, high-efficiency disintegrant system. The formulation must avoid excessive expansion before the salts disperse, since rapid swelling can slow dissolution or create an uncomfortable mouthfeel if patients chew or partially dissolve tablets.

Can lubricants reduce manufacturing defects?

Magnesium stearate is effective but can over-lubricate blends. Excessive lubrication can reduce tablet hardness, slow wetting, and increase dissolution variability. Sodium stearyl fumarate or low-level alternative lubricant systems may offer a development path, particularly for high-speed compression.

A replacement lubricant would need to maintain:

• Low ejection force
• Low punch adhesion
• Adequate tensile strength
• Consistent disintegration
• Acceptable impurity and stability profiles

The opportunity is strongest for contract manufacturers and generic developers seeking higher press speeds or lower defect rates rather than for a major change in patient experience.

Is moisture protection a significant opportunity?

Yes. Sulfate salts and excipients can be sensitive to humidity, and moisture may alter powder flow, tablet hardness, disintegration, and packaging stability. Silicon dioxide can support flow and moisture management, but packaging is equally important.

Potential commercial improvements include:

• High-barrier blister packaging
• Desiccant-containing bottles
• Unit-dose packaging
• Improved bottle closure systems
• Reduced headspace humidity
• Moisture-controlled manufacturing rooms

Packaging patents may provide a separate protection layer from formulation patents. A manufacturer that achieves equivalent stability with simpler packaging could reduce cost. A manufacturer that improves protection without increasing packaging complexity could differentiate through global distribution and longer shelf-life performance.

What patents protect SUTAB and when does SUTAB lose exclusivity?

SUTAB’s protection is likely divided among formulation, dosage-form, manufacturing, and method-of-use rights. The relevant rights must be assessed through the current FDA Orange Book, USPTO records, assignment data, and litigation dockets. Patent listings can change through corrections, delistings, terminal disclaimers, patent-term adjustment, or court decisions.

Protection category	Likely subject matter	Competitive effect
Composition and formulation	Specific combination of sulfate salts, potassium chloride, and excipients	May limit closely matching tablet formulations
Solid dosage form	Tablet architecture, compression characteristics, or dosage configuration	May affect generic tablet design
Method of use	Colon cleansing regimen, split dosing, or administration with water	May limit labeled generic instructions
Manufacturing	Blending, granulation, compression, or stability processes	Usually more difficult to enforce against an unobserved process
Packaging	Moisture barrier, unit dosing, or presentation	Can support lifecycle management

FDA approval does not itself establish patent expiry. FDA marketing exclusivity and patent exclusivity are separate rights. SUTAB received approval in 2018, but the product’s commercial entry date depends on the applicable Orange Book patents, pediatric exclusivity, any patent-term adjustment, and the outcome of Paragraph IV litigation.

A precise loss-of-exclusivity date should not be inferred from the 2018 approval date. For business planning, an applicant should model at least three scenarios:

Scenario	Commercial assumption
Earliest generic entry	Relevant patent is invalidated, not infringed, or otherwise unavailable to block approval
Expected entry	Settlement permits launch on a negotiated date before the latest patent expiry
Delayed entry	Listed patents remain enforceable through their adjusted expiry dates

What is the Orange Book status of SUTAB?

SUTAB is an FDA-approved prescription drug and is evaluated through the small-molecule drug framework. Its reference listing and associated patent information are maintained through FDA’s Orange Book system. An ANDA applicant would generally need to identify the reference listed drug and address listed patents through Paragraph I, II, III, or IV certifications, as applicable. [3]

The key Orange Book questions are:

• Whether SUTAB is listed as the reference listed drug for the proposed tablet.
• Which patents are currently listed against the product.
• Whether any listed patent has pediatric exclusivity.
• Whether method-of-use patents can be carved out through a Section viii statement.
• Whether the proposed generic has the same strength, route, dosage form, and active ingredients.
• Whether differences in inactive ingredients require additional justification.

A generic applicant can use different excipients if the product remains pharmaceutically equivalent and the differences do not affect safety or performance. The applicant must demonstrate bioequivalence and satisfy FDA requirements for inactive ingredients, dissolution, stability, manufacturing controls, and labeling.

Which companies are challenging SUTAB?

Publicly verified challenger activity should be tracked through FDA Paragraph IV notices, district-court complaints, and the Orange Book patent listing. A Paragraph IV certification is not itself proof that a generic will launch. It indicates that the applicant asserts a listed patent is invalid, unenforceable, or not infringed.

Potential challengers have several strategic options:

Paragraph IV challenge

This approach may create a 180-day generic exclusivity opportunity for the first successful ANDA applicant, but it carries litigation costs and launch risk. The commercial case depends on the size of the bowel-preparation market, the strength of the formulation claims, and the availability of non-infringing tablet designs.

Section viii carve-out

A method-of-use patent may be avoided if the generic label omits the protected use and the remaining labeling supports approval. This strategy is more difficult when the patented regimen is central to the product’s intended use.

Formulation redesign

A generic company can alter excipients, tablet shape, coating, packaging, or manufacturing processes while preserving the same active ingredients and strength. The main risk is that the redesigned product may fail comparative dissolution, stability, or bioequivalence requirements.

What generic entry risks exist for SUTAB?

The most important risks are formulation proximity and patient-use complexity.

SUTAB requires 24 tablets and substantial water intake. A generic applicant must match the pharmacologic and pharmaceutical performance of a product with a high active load. Small changes in lubricant level, disintegrant type, particle size, or compression force can change disintegration and dissolution.

Commercial risks include:

• Generic tablet size that patients perceive as harder to swallow
• Higher tablet breakage during distribution
• Packaging that increases moisture exposure
• Manufacturing costs that erase the price advantage
• Physician preference for established bowel-preparation brands
• Payer substitution toward lower-cost liquid products
• Limited market share if colonoscopy centers standardize on other regimens

Generic entry would likely pressure net pricing before it eliminates branded demand. SUTAB may retain volume among patients who prefer tablets or who have difficulty tolerating large-volume liquid preparations.

How does SUTAB compare with liquid bowel preparations?

Attribute	SUTAB	Large-volume liquid preparation
Dosage form	Tablet	Oral solution or powder for solution
Tablet burden	24 tablets	Lower solid-dose burden
Water requirement	High	High, depending on product
Excipient focus	Compression, disintegration, flow, moisture control	Solubility, flavor, osmolarity, suspension stability
Manufacturing challenge	High active mass per tablet	Uniform liquid or powder blending
Patient differentiation	Avoids drinking a large volume of medicated liquid	Avoids swallowing many tablets
Generic barrier	Tablet formulation and equivalence	Solution composition and taste system

SUTAB’s principal commercial value is route and dosage-form differentiation rather than a novel active ingredient. Its strongest market position is among patients and physicians seeking a tablet-based regimen.

What commercial opportunities exist for SUTAB excipients?

Generic and authorized-generic supply

Excipient suppliers can target high-purity microcrystalline cellulose, crospovidone, silicon dioxide, and alternative lubricants. The opportunity is strongest for suppliers that can provide consistent particle-size distribution, low moisture, global regulatory documentation, and reliable supply.

Co-processed excipient systems

A co-processed filler-disintegrant or flow-enhancing system could reduce compression defects and improve production economics. The product must not materially increase tablet volume, because the 24-tablet regimen is already burdensome.

Improved moisture-barrier packaging

Packaging companies can develop lower-cost high-barrier bottles, desiccant closures, or unit-dose blister systems. Packaging changes may support lifecycle management without changing the active formulation.

Smaller or easier-to-swallow tablets

A redesigned tablet may use more efficient compression, altered geometry, or a multilayer structure. The commercial benefit would come from improved patient acceptance rather than reduced total active mass.

International registration

SUTAB-style formulations may have opportunities in markets where colonoscopy volumes are rising and tablet-based bowel preparation is underdeveloped. Geographic expansion requires country-specific review of excipient acceptability, electrolyte warnings, labeling, packaging, and manufacturing standards.

Combination bowel-preparation platforms

A company could develop a broader portfolio covering tablet, powder, and liquid formats. Shared excipient sourcing, packaging, and contract manufacturing could reduce cost and provide physicians with multiple preparation options.

How strong is the SUTAB patent estate?

The estate is strongest when claims cover the specific combination of active salts, tablet format, dosing regimen, and formulation performance. It is weaker where generic applicants can preserve the same active ingredients while changing excipients, tablet geometry, manufacturing conditions, or packaging.

Formulation patents can be commercially useful but are vulnerable to design-around strategies. Method-of-use claims may be important if the dosing sequence and water administration are claimed narrowly. Manufacturing claims have value when process steps are difficult to observe or when the process produces a distinctive product profile.

The practical strength of the estate depends on claim scope, prosecution history, written-description support, enforceability, patent-term adjustment, and the existence of non-infringing formulations. A patent count alone is not a reliable measure of entry risk.

What patent litigation and settlement issues affect SUTAB?

A Paragraph IV case could determine whether a generic may launch before the latest listed patent expiry. The critical documents are the complaint, claim-construction orders, infringement and invalidity opinions, settlement terms, and any FDA notice concerning tentative or final approval.

A settlement may provide:

• A licensed launch date
• A supply or authorized-generic arrangement
• A covenant not to sue
• Restrictions on product design
• Compensation or commercial terms
• A negotiated resolution without a final validity ruling

The absence of a final judgment does not mean the patent estate is weak. Conversely, a settlement launch date does not confirm that every listed patent is enforceable through its nominal expiration.

What revenue exposure does generic entry create?

SUTAB revenue is not separately disclosed in a public filing by Sebela comparable to a public-company product-level disclosure. Exposure therefore depends on prescription volume, net price, payer mix, and the share of patients willing to use tablets rather than liquids.

A practical sensitivity model is:

Variable	Downside case	Base case	Upside case
Generic discount to branded net price	70%	50%	30%
Branded volume retained after entry	20%	40%	60%
Tablet-prep market growth	Flat	Low single digit	Mid single digit
Primary value driver	Price erosion	Mixed price and volume	Differentiated adherence

The largest commercial risk is not immediate product disappearance. It is rapid payer substitution combined with lower branded reimbursement. Lifecycle value can be preserved through supply reliability, patient-support programs, packaging improvements, and differentiated tablet usability.

Key Takeaways

• SUTAB contains 24 tablets per full regimen and approximately 45.4 g of active sulfate and potassium salts.
• Its disclosed excipients are crospovidone, magnesium stearate, microcrystalline cellulose, and silicon dioxide.
• The main formulation priorities are compression, disintegration, moisture control, flow, and tablet acceptability.
• Excipient substitution is possible for generic applicants but must support pharmaceutical equivalence and FDA approval.
• Packaging and manufacturing improvements may create commercial value without changing the active formulation.
• SUTAB is a small-molecule drug, so biosimilar competition does not apply.
• Generic entry risk depends on Orange Book patents, Paragraph IV activity, formulation design-arounds, litigation outcomes, and settlement terms.
• The strongest commercial opportunity is likely a lower-cost, moisture-stable, mechanically robust tablet with equivalent performance and improved manufacturing economics.

FAQs

Can a generic SUTAB use different inactive ingredients?

Yes. A generic applicant may use different excipients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, stability, safety, dissolution, and labeling.

Why is SUTAB difficult to formulate?

The active salts create a high tablet mass, while the regimen requires 24 tablets. The formulation must balance tablet strength, disintegration, flow, moisture stability, and patient swallowability.

Is SUTAB protected by a method-of-use patent?

Method-of-use protection may cover the colon-cleansing regimen, split dosing, or administration instructions. The current Orange Book listing and patent claims determine the practical scope.

Can SUTAB tablets become substantially smaller?

Only to a limited extent because the active ingredients represent most of the tablet mass. Tablet geometry, compression efficiency, and excipient selection may improve handling and swallowability without materially reducing total mass.

Is an authorized generic the main threat to SUTAB?

An authorized generic could accelerate price erosion, but an independent ANDA applicant may create greater long-term pressure if it obtains approval with a non-infringing formulation and secures broad payer substitution.

References

1. U.S. Food and Drug Administration. (2024). SUTAB (sodium sulfate, magnesium sulfate, and potassium chloride) tablets: Prescribing information. Sebela Pharmaceuticals.

2. U.S. Food and Drug Administration. (2018). FDA approves SUTAB for colon cleansing prior to colonoscopy in adults. FDA Drugs@FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.